These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7838659)

  • 1. Deflazacort in pediatric rheumatic diseases needs a frequent follow-up of bone densitometry.
    Falcini F; Trapani S; Ermini M; Bartolozzi G
    Pediatrics; 1995 Feb; 95(2):318. PubMed ID: 7838659
    [No Abstract]   [Full Text] [Related]  

  • 2. [Glucocorticoids and risk of osteoporosis. On the problem of equivalent dose of desirable and undesirable effects of various glucocorticoids, exemplified by deflazacort].
    Rotenberger J; Köbberling J
    Med Klin (Munich); 1993 Jul; 88(7):432-7. PubMed ID: 8377721
    [No Abstract]   [Full Text] [Related]  

  • 3. [Deflazacort is an effective and safe alternative to current corticoids].
    Med Clin (Barc); 1991 Mar; 96(8):suppl 1p.. PubMed ID: 2041397
    [No Abstract]   [Full Text] [Related]  

  • 4. Does deflazacort therapy offer any advantages over conventional corticosteroids in children with renal disease?
    Clark G
    Pediatr Nephrol; 1997 Jun; 11(3):394. PubMed ID: 9203206
    [No Abstract]   [Full Text] [Related]  

  • 5. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
    LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
    Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deflazacort in giant cell arteritis.
    Devogelaer JP; Gennari C
    J Rheumatol; 2002 Oct; 29(10):2244-5. PubMed ID: 12375347
    [No Abstract]   [Full Text] [Related]  

  • 7. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study.
    Saviola G; Abdi Ali L; Shams Eddin S; Coppini A; Cavalieri F; Campostrini L; Sacco S; Bucci M; Cirino G; Rossini M
    Rheumatology (Oxford); 2007 Jun; 46(6):994-8. PubMed ID: 17384176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
    J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary experience with deflazacort, a new synthetic steroid with fewer undesirable side effects, in heart transplant patients.
    Arizón JM; Anguita M; Vallés F; Montero A; Sancho M; López-Rubio F; Latre JM; Calleja F; Casares J; Román M
    J Heart Lung Transplant; 1993; 12(3):445-8; discussion 448-9. PubMed ID: 8329416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posterior subcapsular cataracts associated with deflazacort therapy.
    Krmar RT; Ramirez JA; Torres CG; Ferraris JR
    Clin Nephrol; 1997 Mar; 47(3):205. PubMed ID: 9105772
    [No Abstract]   [Full Text] [Related]  

  • 11. [Significance of cytokines for bone loss--are there possible interventions?].
    Scharla SH
    Z Rheumatol; 2001 Apr; 60(2):104-6. PubMed ID: 11383043
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of prednisone and deflazacort on vertebral bone mass.
    Gennari C; Imbimbo B
    Calcif Tissue Int; 1985 Dec; 37(6):592-3. PubMed ID: 3937579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic trial of a new topical anti-inflammatory agent].
    Jezequel J; Becuwe B; Daniel C; Geraudel O
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1979 Jan; 28(1):65-6, 68. PubMed ID: 155139
    [No Abstract]   [Full Text] [Related]  

  • 14. [Non-steroidal anti-inflammatory drugs in the treatment of rheumatic diseases].
    Olhagen B
    Nord Med; 1985; 100(1):11-3. PubMed ID: 3875835
    [No Abstract]   [Full Text] [Related]  

  • 15. Natural and corticosteroid-induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility.
    Rizzato G; Fraioli P
    Sarcoidosis; 1990 Sep; 7(2):89-92. PubMed ID: 2255799
    [No Abstract]   [Full Text] [Related]  

  • 16. Intraarticular use of Gordox in rheumatic diseases.
    Varjas K; Bobkó G
    Ther Hung; 1977; 25(4):157-61. PubMed ID: 305138
    [No Abstract]   [Full Text] [Related]  

  • 17. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up.
    Houde S; Filiatrault M; Fournier A; Dubé J; D'Arcy S; Bérubé D; Brousseau Y; Lapierre G; Vanasse M
    Pediatr Neurol; 2008 Mar; 38(3):200-6. PubMed ID: 18279756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis.
    Rebollo Bernárdez J; Cifuentes Mimoso C; Piñar Moreno A; Caunedo Alvarez A; Salas Herrero E; Jiménez-Sáenz M; Herrerías Gutiérrez J
    Rev Esp Enferm Dig; 1999 Sep; 91(9):630-8. PubMed ID: 10502711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort].
    Krogsgaard MR; Thamsborg G; Lund B
    Ugeskr Laeger; 1997 Jul; 159(30):4641-4. PubMed ID: 9245040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deflazacort in the treatment of uveitis: a comparative study versus prednisone.
    Cerqueti Piera M; Saccà Sergio C; Allegri P; Ciurlo G; Zingirian M; Buscaglia S; Ciprandi G
    Allergol Immunopathol (Madr); 1993; 21(3):107-10. PubMed ID: 8356936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.